This Month in Psychopharmacology

Browsing articles in "Psychotic Disorders"

Substance-Induced Psychosis Tied to Schizophrenia Risk
October 17, 2023

individuals without a history of psychosis were assessed for the likelihood of transitioning to schizophrenia following an episode of substance-induced psychosis....

Continue reading (Members only)

Sexual Dysfunction in Schizophrenia
October 9, 2023

Schizophrenia has high prevalence rates of sexual dysfunction; however, antipsychotic medications explain a significant source of variability in these prevalence rates. Antipsychotics have varying effects on sexual function due to their impact on ...

Continue reading (Members only)

Antipsychotic Polypharmacy Increases Risk of Hypertension, Study Suggests
September 21, 2023

In some cases, treating schizophrenia is especially difficult and may result in the patient receiving two antipsychotic prescriptions to manage symptoms. Although it is known that antipsychotic polypharmacy increases the risk of developing movement disorders, there is also worry that antipsychotic polypharmacy may increase the risk of developing diabetes, hypertension, or hyperlipidemia...

Continue reading (Members only)

Brain Volume Patterns Vary Across Psychiatric Disorders
September 5, 2023

Differential diagnosis of, and perhaps development of effective treatments for, psychiatric conditions would certainly be easier if we had reliable biomarkers such as neuroimaging. Unfortunately, such biomarkers do not currently exist; in the treasure hunt for a neuroimaging biomarker for a specific psychiatric illness, there is no..

Continue reading (Members only)

Schizophrenia Treatment Fails to Meet Primary Endpoint in Phase 3 Clinical Studies
August 15, 2023

Recent trials for the TAAR1 agonist ulotaront to treat schizophrenia failed phase 3 clinical trials. The Developing Innovative Approaches for Mental Disorders (DIAMOND) series of clinical trials tested ulotaront dosed once-daily in acutely psychotic adults living with schizophrenia...

Continue reading (Members only)

World Schizophrenia Day: Education and Tool for Providers
May 24, 2023

The high rates of treatment resistance, relapse rates, and incidence of adverse effects in patients with schizophrenia suggest that a major treatment gap continues to still exist. Education is an essential tool in order for clinicians to integrate the new data, treatment options, and recommended management strategies into clinical practice as they become available...

New Tool Accurately Predicts Suicide Risk in Serious Mental Illness
May 7, 2023

Arguably the worst outcome in mental illness is death by suicide, and one of the greatest challenges in the mental heath care field is accurately determining which patients are at high risk of suicide so that intervening measures can be implemented. The Oxford Mental Illness and Suicide Tool (OxMIS) is a risk assessment tool designed to measure suicide risk in patients with severe mental illness...

Continue reading (Members only)

FDA Approves Slow-Release Long-Acting Injectable of Risperidone
April 28, 2023

The U.S. Food and Drug Administration has approved extended-release injectable suspension of risperidone for the treatment of schizophrenia in adults...

FDA Approves Aripiprazole as First Once-Every-2-Months Long-Acting Injectable for Schizophrenia, Bipolar I Disorder
April 27, 2023

The U.S. Food and Drug Administration has approved a new drug application for a once-every-two-months long-acting injectable version of aripiprazole for the treatment of schizophrenia in adults or for maintenance monotherapy treatment of bipolar I disorder in adults...

High Dose Antipsychotic Polypharmacy and Hospitalization Risk
April 13, 2023

Historically, practice guidelines have recommended antipsychotic monotherapy over polypharmacy -partially due to concerns over the safety of utilizing two antipsychotics at the same time. A recent study compared antipsychotic monotherapy with antipsychotic polypharmacy in terms of safety (specifically nonpsychiatric hospitalization and hospitalization for cardiovascular reasons) and risk of relapse (as indicated by psychiatric hospitalization) at various defined daily doses...

Continue reading (Members only)

Top of Page